Announcement • May 16
Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 24, 2026 Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 24, 2026. Reported Earnings • May 14
Full year 2026 earnings: EPS and revenues exceed analyst expectations Full year 2026 results: EPS: JP¥152 (up from JP¥136 in FY 2025). Revenue: JP¥343.7b (up 11% from FY 2025). Net income: JP¥34.2b (up 11% from FY 2025). Profit margin: 10.0% (in line with FY 2025). Revenue exceeded analyst estimates by 1.4%. Earnings per share (EPS) also surpassed analyst estimates by 3.7%. Revenue is forecast to grow 4.1% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Personal Products industry in Japan. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Live News • May 09
AVI Presses Rohto Pharmaceutical to Refocus on Core Business Ahead of 2026 Chairman Vote Asset Value Investors (AVI) has updated its public campaign urging Rohto Pharmaceutical to prioritize core businesses and reduce its focus on regenerative medicine.
AVI criticizes Rohto’s continued investment in regenerative medicine, arguing there is no clear path to profitability and raising governance concerns around Chairman Kunio Yamada.
AVI plans to submit a shareholder proposal to dismiss Chairman Yamada at Rohto’s June 2026 Annual General Meeting.
For investors, the key issue is the tension between Rohto’s capital allocation toward regenerative medicine and AVI’s push for a tighter focus on existing core operations. AVI is framing regenerative medicine as a high-cost area without sufficient visibility on returns, and is directly challenging the board’s oversight under the current chairman.
The intention to file a proposal to remove the chairman sets up a potential governance showdown at the June 2026 AGM. That could influence how Rohto thinks about investment priorities, risk appetite and communication with shareholders over the next year. Investors will likely watch for Rohto’s formal response to AVI’s campaign, any changes in disclosure around the regenerative medicine business and whether other shareholders publicly back AVI’s position. Announcement • May 09
Rohto Pharmaceutical Co.,Ltd. to Report Fiscal Year 2026 Results on May 13, 2026 Rohto Pharmaceutical Co.,Ltd. announced that they will report fiscal year 2026 results on May 13, 2026 Announcement • Mar 26
Rohto Pharmaceutical Co.,Ltd. (TSE:4527) announces an Equity Buyback for 1,500,000 shares, representing 0.66% for ¥3,000 million. Rohto Pharmaceutical Co.,Ltd. (TSE:4527) announces a share repurchase program. Under the program, the company will repurchase up to 1,500,000 shares, representing 0.66% of its share capital, for ¥3,000 million. The purpose of the program is to improve capital efficiency and enable the flexible execution of capital policies. The program will expire on December 31, 2026. As of March 26, 2026, the company had 225,964,340 shares in issue (excluding treasury stock) and 10,213,970 shares in treasury. Upcoming Dividend • Mar 23
Upcoming dividend of JP¥23.00 per share Eligible shareholders must have bought the stock before 30 March 2026. Payment date: 12 June 2026. Payout ratio is a comfortable 27% and this is well supported by cash flows. Trailing yield: 2.0%. Lower than top quartile of Japanese dividend payers (3.6%). Lower than average of industry peers (2.4%). Reported Earnings • Feb 14
Third quarter 2026 earnings: EPS exceeds analyst expectations while revenues lag behind Third quarter 2026 results: EPS: JP¥47.03 (down from JP¥52.10 in 3Q 2025). Revenue: JP¥88.8b (up 2.3% from 3Q 2025). Net income: JP¥10.6b (down 11% from 3Q 2025). Profit margin: 12% (down from 14% in 3Q 2025). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 2.9%. Earnings per share (EPS) exceeded analyst estimates by 6.6%. Revenue is forecast to grow 4.5% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Personal Products industry in Japan. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Announcement • Jan 08
Rohto Pharmaceutical Co.,Ltd. (TSE:4527) entered into a share acquisition agreement to acquire 51% stake in Thann Oryza Company Limited from Thitipat Suppattranont and others. Rohto Pharmaceutical Co.,Ltd. (TSE:4527) entered into a share acquisition agreement to acquire 51% stake in Thann Oryza Company Limited from Thitipat Suppattranont and others on January 7, 2026.
The expected completion of the transaction is March 31, 2026. Declared Dividend • Dec 05
First half dividend of JP¥22.00 announced Shareholders will receive a dividend of JP¥22.00. Ex-date: 30th March 2026 Payment date: 12th June 2026 Dividend yield will be 1.8%, which is lower than the industry average of 2.0%. Sustainability & Growth Dividend is well covered by both earnings (26% earnings payout ratio) and cash flows (33% cash payout ratio). The dividend has increased by an average of 16% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 8.2% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Announcement • Dec 04
Rohto Pharmaceutical Co.,Ltd. to Report Q3, 2026 Results on Feb 12, 2026 Rohto Pharmaceutical Co.,Ltd. announced that they will report Q3, 2026 results on Feb 12, 2026 Reported Earnings • Nov 15
Second quarter 2026 earnings: EPS exceeds analyst expectations Second quarter 2026 results: EPS: JP¥26.04 (up from JP¥19.46 in 2Q 2025). Revenue: JP¥82.3b (up 16% from 2Q 2025). Net income: JP¥5.88b (up 33% from 2Q 2025). Profit margin: 7.1% (up from 6.3% in 2Q 2025). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 4.5%. Revenue is forecast to grow 3.7% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Personal Products industry in Japan. Over the last 3 years on average, earnings per share has increased by 10% per year whereas the company’s share price has increased by 5% per year. Upcoming Dividend • Sep 22
Upcoming dividend of JP¥21.00 per share Eligible shareholders must have bought the stock before 29 September 2025. Payment date: 05 December 2025. Payout ratio is a comfortable 24% and this is well supported by cash flows. Trailing yield: 1.6%. Lower than top quartile of Japanese dividend payers (3.6%). Lower than average of industry peers (2.2%). Announcement • Aug 28
Rohto Pharmaceutical Co.,Ltd. to Report Q2, 2026 Results on Nov 13, 2025 Rohto Pharmaceutical Co.,Ltd. announced that they will report Q2, 2026 results on Nov 13, 2025 Valuation Update With 7 Day Price Move • Aug 13
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to JP¥2,488, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 27x in the Personal Products industry in Japan. Total returns to shareholders of 20% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at JP¥3,492 per share. Reported Earnings • Aug 07
First quarter 2026 earnings released: EPS: JP¥52.08 (vs JP¥37.18 in 1Q 2025) First quarter 2026 results: EPS: JP¥52.08 (up from JP¥37.18 in 1Q 2025). Revenue: JP¥82.0b (up 20% from 1Q 2025). Net income: JP¥11.8b (up 39% from 1Q 2025). Profit margin: 14% (up from 12% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Personal Products industry in Japan. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Declared Dividend • Jul 09
Final dividend of JP¥21.00 announced Shareholders will receive a dividend of JP¥21.00. Ex-date: 29th September 2025 Payment date: 5th December 2025 Dividend yield will be 2.0%, which is about the same as the industry average. Sustainability & Growth Dividend is well covered by both earnings (24% earnings payout ratio) and cash flows (36% cash payout ratio). The dividend has increased by an average of 15% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 20% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Jul 01
Full year 2025 earnings: EPS in line with expectations, revenues disappoint Full year 2025 results: EPS: JP¥136 (up from JP¥136 in FY 2024). Revenue: JP¥308.6b (up 14% from FY 2024). Net income: JP¥31.0b (flat on FY 2024). Profit margin: 10.0% (down from 11% in FY 2024). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 1.3%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Personal Products industry in Japan. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Announcement • Jun 03
Rohto Pharmaceutical Co.,Ltd. to Report Q1, 2026 Results on Aug 06, 2025 Rohto Pharmaceutical Co.,Ltd. announced that they will report Q1, 2026 results on Aug 06, 2025 Valuation Update With 7 Day Price Move • May 20
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to JP¥2,049, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 23x in the Personal Products industry in Japan. Total returns to shareholders of 21% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at JP¥3,609 per share. Reported Earnings • May 14
Full year 2025 earnings: EPS in line with expectations, revenues disappoint Full year 2025 results: EPS: JP¥136 (up from JP¥136 in FY 2024). Revenue: JP¥308.6b (up 14% from FY 2024). Net income: JP¥31.0b (flat on FY 2024). Profit margin: 10.0% (down from 11% in FY 2024). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 1.3%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Personal Products industry in Japan. Over the last 3 years on average, earnings per share has increased by 11% per year whereas the company’s share price has increased by 9% per year. Announcement • May 13
Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 26, 2025 Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 26, 2025. Valuation Update With 7 Day Price Move • Apr 14
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to JP¥2,414, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 22x in the Personal Products industry in Japan. Total returns to shareholders of 51% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at JP¥3,595 per share. Price Target Changed • Apr 02
Price target decreased by 7.8% to JP¥2,986 Down from JP¥3,239, the current price target is an average from 8 analysts. New target price is 35% above last closing price of JP¥2,212. Stock is down 27% over the past year. The company posted earnings per share of JP¥136 last year. Upcoming Dividend • Mar 21
Upcoming dividend of JP¥20.00 per share Eligible shareholders must have bought the stock before 28 March 2025. Payment date: 13 June 2025. Payout ratio is a comfortable 24% and this is well supported by cash flows. Trailing yield: 1.8%. Lower than top quartile of Japanese dividend payers (3.7%). Lower than average of industry peers (2.2%). Announcement • Mar 01
Rohto Pharmaceutical Co.,Ltd. to Report Fiscal Year 2025 Results on May 13, 2025 Rohto Pharmaceutical Co.,Ltd. announced that they will report fiscal year 2025 results on May 13, 2025 New Risk • Feb 28
New minor risk - Dividend sustainability The company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 1.8% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company. Announcement • Feb 27
Rohto Pharmaceutical Co.,Ltd. (TSE:4527) announces an Equity Buyback for 2,430,000 shares, representing 1.07% for ¥5,000 million. Rohto Pharmaceutical Co., Ltd. (TSE:4527) announces a share repurchase program. Under the program, the company will repurchase up to 2,430,000 shares, representing 1.07% of its issued share capital, for a total cost of up to ¥5,000 million. The plan will continue until April 30, 2025. Announcement • Feb 26
Rohto Pharmaceutical Co.,Ltd. (TSE:4527) announces an Equity Buyback for 2,430,000 shares, representing 1.07% for ¥5,000 million. Rohto Pharmaceutical Co.,Ltd. (TSE:4527) announces a share repurchase program. Under the program, the company will repurchase up to 2,430,000 shares, representing 1.07% of its share capital, for ¥5,000 million. The purpose of the program is to improve ROE and earnings per share (EPS), mitigate the short-term impact on the supply and demand of its shares from the issuance of Euro-yen convertible bonds with stock acquisition rights due in 2032, and facilitate fund procurement. The program will expire on April 30, 2025. As of December 31, 2024, the company had 228,138,738 shares in issue (excluding treasury stock) and 8,039,572 shares in treasury. Reported Earnings • Feb 13
Third quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Third quarter 2025 results: EPS: JP¥52.10 (up from JP¥41.92 in 3Q 2024). Revenue: JP¥86.8b (up 18% from 3Q 2024). Net income: JP¥11.9b (up 24% from 3Q 2024). Profit margin: 14% (in line with 3Q 2024). Revenue missed analyst estimates by 3.0%. Earnings per share (EPS) exceeded analyst estimates by 6.1%. Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Personal Products industry in Japan. Over the last 3 years on average, earnings per share has increased by 11% per year whereas the company’s share price has increased by 9% per year. Announcement • Feb 12
Rohto Pharmaceutical Co.,Ltd. Revises Dividend Guidance for the Fiscal Year Ending March 31, 2025 Rohto Pharmaceutical Co.,Ltd. revised dividend guidance for the fiscal Year Ending March 31, 2025. For the year, the company expects dividend of JPY 20.00 per share compared to JPY 17.00 per share a year ago. Reasons for the revisions: Consistently and continually returning to shareholders the profits earned through business activities is one of the highest priorities. The fundamental policy is to pay a dividend based on results of operations. Based on the earnings forecast for the fiscal year ending March 31, 2025 (April 1, 2024 to March 31, 2025), to enhance the return of profits to shareholders, for said fiscal year, the Company has decided to increase the year-end dividend by JPY 3 to JPY 20 per share. As such, the total annual dividend will be JPY 36 per share. Price Target Changed • Jan 01
Price target decreased by 7.8% to JP¥3,510 Down from JP¥3,806, the current price target is an average from 9 analysts. New target price is 22% above last closing price of JP¥2,878. Stock is up 1.2% over the past year. The company is forecast to post earnings per share of JP¥139 for next year compared to JP¥136 last year. Declared Dividend • Dec 06
First half dividend of JP¥17.00 announced Shareholders will receive a dividend of JP¥17.00. Ex-date: 28th March 2025 Payment date: 13th June 2025 Dividend yield will be 1.2%, which is lower than the industry average of 2.0%. Sustainability & Growth Dividend is well covered by both earnings (13% earnings payout ratio) and cash flows (26% cash payout ratio). The dividend has increased by an average of 14% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 41% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Announcement • Nov 29
Rohto Pharmaceutical Co.,Ltd. to Report Q3, 2025 Results on Feb 12, 2025 Rohto Pharmaceutical Co.,Ltd. announced that they will report Q3, 2025 results on Feb 12, 2025 Reported Earnings • Nov 15
Second quarter 2025 earnings: EPS and revenues miss analyst expectations Second quarter 2025 results: EPS: JP¥19.46 (down from JP¥32.89 in 2Q 2024). Revenue: JP¥70.7b (up 6.0% from 2Q 2024). Net income: JP¥4.44b (down 41% from 2Q 2024). Profit margin: 6.3% (down from 11% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 1.9%. Earnings per share (EPS) also missed analyst estimates by 45%. Revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Personal Products industry in Japan. Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 18% per year. New Risk • Nov 14
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 3.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Valuation Update With 7 Day Price Move • Nov 14
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to JP¥2,736, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 24x in the Personal Products industry in Japan. Total returns to shareholders of 71% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at JP¥4,467 per share. Buy Or Sell Opportunity • Oct 05
Now 21% undervalued Over the last 90 days, the stock has risen 8.0% to JP¥3,524. The fair value is estimated to be JP¥4,482, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 16%. For the next 3 years, revenue is forecast to grow by 9.0% per annum. Earnings are also forecast to grow by 10% per annum over the same time period. Upcoming Dividend • Sep 20
Upcoming dividend of JP¥16.00 per share Eligible shareholders must have bought the stock before 27 September 2024. Payment date: 09 December 2024. Payout ratio is a comfortable 20% and this is well supported by cash flows. Trailing yield: 0.9%. Lower than top quartile of Japanese dividend payers (3.8%). Lower than average of industry peers (2.0%). Buy Or Sell Opportunity • Sep 11
Now 20% undervalued Over the last 90 days, the stock has risen 22% to JP¥3,565. The fair value is estimated to be JP¥4,472, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 16%. For the next 3 years, revenue is forecast to grow by 8.8% per annum. Earnings are also forecast to grow by 10% per annum over the same time period. Announcement • Aug 28
Rohto Pharmaceutical Co.,Ltd. to Report Q2, 2025 Results on Nov 13, 2024 Rohto Pharmaceutical Co.,Ltd. announced that they will report Q2, 2025 results on Nov 13, 2024 Reported Earnings • Aug 09
First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind First quarter 2025 results: EPS: JP¥37.18 (down from JP¥39.84 in 1Q 2024). Revenue: JP¥68.4b (up 12% from 1Q 2024). Net income: JP¥8.48b (down 6.7% from 1Q 2024). Profit margin: 12% (down from 15% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.0%. Earnings per share (EPS) missed analyst estimates by 6.8%. Revenue is forecast to grow 7.8% p.a. on average during the next 3 years, compared to a 4.1% growth forecast for the Personal Products industry in Japan. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Aug 05
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to JP¥2,987, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 22x in the Personal Products industry in Japan. Total returns to shareholders of 102% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at JP¥4,789 per share. Declared Dividend • Jul 11
Final dividend of JP¥15.00 announced Shareholders will receive a dividend of JP¥15.00. Ex-date: 27th September 2024 Payment date: 9th December 2024 Dividend yield will be 0.9%, which is lower than the industry average of 2.0%. Payout Ratios Payout ratio: 18%. Cash payout ratio: 27%. Buy Or Sell Opportunity • Jul 05
Now 20% undervalued Over the last 90 days, the stock has risen 12% to JP¥3,245. The fair value is estimated to be JP¥4,079, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 18%. For the next 3 years, revenue is forecast to grow by 6.9% per annum. Earnings are also forecast to grow by 9.2% per annum over the same time period. Announcement • Jun 17
Rohto Pharmaceutical Co.,Ltd. to Report Q1, 2025 Results on Aug 07, 2024 Rohto Pharmaceutical Co.,Ltd. announced that they will report Q1, 2025 results on Aug 07, 2024 Announcement • Jun 08
Rohto Pharmaceutical Co.,Ltd. agreed to acquire 51% stake in Mono chem-pharm Produkte Gmbh for €30 million. Rohto Pharmaceutical Co.,Ltd. agreed to acquire additional 51% stake in Mono chem-pharm Produkte Gmbh for €30 million on June 6, 2024. Buy Or Sell Opportunity • May 21
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 6.3% to JP¥2,805. The fair value is estimated to be JP¥3,563, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 18%. For the next 3 years, revenue is forecast to grow by 6.6% per annum. Earnings are also forecast to grow by 11% per annum over the same time period. Reported Earnings • May 16
Full year 2024 earnings: Revenues and EPS in line with analyst expectations Full year 2024 results: EPS: JP¥136 (up from JP¥116 in FY 2023). Revenue: JP¥270.8b (up 14% from FY 2023). Net income: JP¥30.9b (up 17% from FY 2023). Profit margin: 11% (in line with FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Personal Products industry in Japan. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 28% per year, which means it is tracking significantly ahead of earnings growth. Announcement • May 15
Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 27, 2024 Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 27, 2024. Announcement • May 11
Rohto Pharmaceutical Co.,Ltd. to Report Q4, 2024 Results on May 13, 2024 Rohto Pharmaceutical Co.,Ltd. announced that they will report Q4, 2024 results on May 13, 2024 Buy Or Sell Opportunity • Apr 24
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 2.1% to JP¥2,922. The fair value is estimated to be JP¥3,680, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 21%. For the next 3 years, revenue is forecast to grow by 5.5% per annum. Earnings are also forecast to grow by 10% per annum over the same time period. Buy Or Sell Opportunity • Apr 05
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 1.2% to JP¥2,885. The fair value is estimated to be JP¥3,692, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 21%. For the next 3 years, revenue is forecast to grow by 5.3% per annum. Earnings are also forecast to grow by 10% per annum over the same time period. Announcement • Apr 05
Rohto Pharmaceutical Co.,Ltd. (TSE:4527), Mitsui & Co., Ltd. (TSE:8031) and others agreed to acquire an 86% stake in Eu Yan Sang International Ltd from Blanca Investments Pte. Ltd., Tower Capital Asia and founding family for approximately SGD 690 million. Rohto Pharmaceutical Co.,Ltd. (TSE:4527), Mitsui & Co., Ltd. (TSE:8031) and others agreed to acquire an 86% stake in Eu Yan Sang International Ltd from Blanca Investments Pte. Ltd., Tower Capital Asia and founding family for approximately SGD 690 million on April 4, 2024. Eu Yan Sang International has net assets of SGD 149.9 million, total assets of SGD 268.1 million, sales of SGD 297.3 million, net income of SGD 18.7 million and core EBITDA of SGD 42.2 million as of June 30, 2023. Upon the fulfillment of the condition to the Share Acquisition, we will conduct a mandatory general offer for the remaining 14% of the issued ordinary shares of EYS The transaction is expected to complete by June 30, 2024. Upcoming Dividend • Mar 21
Upcoming dividend of JP¥15.00 per share Eligible shareholders must have bought the stock before 28 March 2024. Payment date: 14 June 2024. Payout ratio is a comfortable 9.6% and this is well supported by cash flows. Trailing yield: 0.9%. Lower than top quartile of Japanese dividend payers (3.2%). Lower than average of industry peers (2.1%). Buy Or Sell Opportunity • Mar 13
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 1.6% to JP¥2,861. The fair value is estimated to be JP¥3,611, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 21%. For the next 3 years, revenue is forecast to grow by 6.0% per annum. Earnings are also forecast to grow by 10% per annum over the same time period. Reported Earnings • Feb 10
Third quarter 2024 earnings released: EPS: JP¥41.92 (vs JP¥37.02 in 3Q 2023) Third quarter 2024 results: EPS: JP¥41.92 (up from JP¥37.02 in 3Q 2023). Revenue: JP¥73.3b (up 11% from 3Q 2023). Net income: JP¥9.56b (up 13% from 3Q 2023). Profit margin: 13% (in line with 3Q 2023). Revenue is forecast to grow 7.0% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Personal Products industry in Japan. Over the last 3 years on average, earnings per share has increased by 21% per year whereas the company’s share price has increased by 24% per year. Announcement • Dec 28
Rohto Pharmaceutical Co.,Ltd. to Report Q3, 2024 Results on Feb 09, 2024 Rohto Pharmaceutical Co.,Ltd. announced that they will report Q3, 2024 results on Feb 09, 2024 Price Target Changed • Dec 19
Price target decreased by 7.5% to JP¥3,814 Down from JP¥4,126, the current price target is an average from 7 analysts. New target price is 35% above last closing price of JP¥2,830. Stock is up 26% over the past year. The company is forecast to post earnings per share of JP¥133 for next year compared to JP¥116 last year. Announcement • Nov 12
Rohto Pharmaceutical Co.,Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024 Rohto Pharmaceutical Co.,Ltd. provided consolidated earnings guidance for the fiscal year ending March 31, 2024. The company expects net sales to be JPY 270,000 million, Operating profit to be JPY 38,500 million, profit attributable to owners of parent to be JPY 29,000 million or JPY 127.12 per basic share. 
